(312) 275-5850 9-5pm CST
0 CART $0.00
Your shopping cart is empty.
CIA Medical Google Customer Reviews – Central Infusion Alliance
CIA Medical BBB Accredited A+ Business – Central Infusion Alliance
CIA Medical Digicert EV Secure – Central Infusion Alliance
Menu

BD 2671915 - PowerLoc PAK Safety Infusion Set with Y-Injection Site, 19G x 1.5", 5/CS (Temp Sensitive; Non-Returnable) (Continental US Only)

BD  # 2671915 - PowerLoc PAK Safety Infusion Set with Y-Injection Site, 19G x 1.5
Part Number BD 2671915
SKU Number CIA8043480
Sell Unit CASE
Ships Within Special Order
List Price $235.43
Enter a valid quantity
Product Description

BD 2671915 - PowerLoc PAK Safety Infusion Set with Y-Injection Site, 19G x 1.5", 5/CS (Temp Sensitive; Non-Returnable) (Continental US Only)

The BD 2671915 PowerLoc PAK Safety Infusion Set is a sterile, single-use port-access solution designed for accessing compatible surgically implanted vascular ports. The set features a 19-gauge non-coring needle with a 1.5-inch length and includes a Y-injection site for secondary access to the infusion pathway.

The PowerLoc system provides a fluid pathway for administering compatible medications and solutions, withdrawing blood specimens, flushing implanted ports, and delivering contrast media through appropriately rated power-injectable ports. The 19-gauge configuration supports higher-flow infusion and diagnostic imaging applications, while the 1.5-inch needle length accommodates implanted ports positioned beneath a greater depth of subcutaneous tissue.

An integrated safety mechanism is designed to help reduce accidental needlestick exposure during port deaccessing. As the needle is withdrawn from the implanted port and secured into the protective position, the sharp point becomes shielded to support safer handling and disposal.

The PowerLoc design provides a compact port-access profile for dressing placement, access-site management, and patient care. The winged configuration supports controlled insertion and stabilization, while the tubing arrangement is designed for efficient connection within established infusion workflows.

The PAK presentation provides an organized, all-in-one approach intended to simplify the multi-step sterile port-access preparation process. BD 2671915 is supplied five sets per case.

ManufacturerApplicationNeedle Length
2671915Port Access Kit1-1/2 Inch

Key Benefits

  • 19-gauge non-coring needle supports access to compatible implanted vascular ports.
  • 1.5-inch needle length accommodates ports positioned beneath greater subcutaneous tissue depth.
  • Power-injectable design supports compatible contrast-enhanced imaging procedures.
  • Supports power-injection flow rates up to 5 mL per second when the complete access system is appropriately rated.
  • Y-injection site provides a secondary access point for compatible medication or fluid administration.
  • Non-coring needle design helps preserve the septum of compatible implanted ports during appropriate use.
  • Integrated safety mechanism helps shield the needle following port deaccessing.
  • Safety design supports occupational needlestick-prevention practices.
  • Winged configuration supports controlled insertion and stabilization.
  • Compact profile supports dressing application and ongoing access-site management.
  • Suitable for appropriate infusion, blood sampling, port maintenance, and diagnostic imaging workflows.
  • PAK format helps organize essential supplies for sterile port-access preparation.
  • Five-per-case packaging supports clinical inventory management.

Compatibility and Applications

The BD 2671915 PowerLoc PAK Safety Infusion Set is intended for use with compatible surgically implanted vascular access ports designed to accept non-coring port-access needles.

Potential clinical applications include chemotherapy administration, antibiotic therapy, hydration, parenteral nutrition, blood product administration, long-term infusion therapy, blood specimen collection, implanted port flushing, and contrast-media delivery during compatible diagnostic imaging procedures.

The 19-gauge configuration may be selected when higher flow capability is required and the implanted port, prescribed therapy, and complete fluid pathway are compatible with a larger-gauge access needle. Selection should consider medication viscosity, required flow rate, infusion-pump parameters, power-injection requirements, and manufacturer instructions.

The 1.5-inch needle length is intended for deeper implanted port placements or patients with greater tissue depth over the port septum. A needle that is too short may not completely access the septum, while an unnecessarily long needle may affect stabilization and dressing placement.

The integrated Y-injection site provides an additional access point within the tubing. It may support compatible intermittent medication administration, flushing, or connection of another approved fluid pathway when permitted by the clinical procedure and institutional protocol.

For power injection, the implanted port, access needle, tubing, connectors, Y-site, extension components, and every other component within the fluid pathway must be specifically rated for the intended procedure. The lowest-rated component determines the maximum allowable pressure and flow rate.

Compatibility should be confirmed with the implanted port model, septum design, port depth, prescribed therapy, infusion pump, power injector, connector system, dressing materials, and institutional vascular-access procedures.

Usage Guidelines

The BD 2671915 should be used only by healthcare professionals who are trained and authorized to access implanted vascular ports. Current manufacturer instructions, aseptic technique, institutional procedures, and the implanted port manufacturer's directions should be followed throughout the procedure.

  • Confirm the patient's identity, prescribed therapy, implanted port type, and power-injection status.
  • Assess the location and depth of the implanted port before selecting the 1.5-inch needle.
  • Verify that the 19-gauge configuration is appropriate for the intended infusion or imaging procedure.
  • Confirm that the Y-injection site configuration is suitable for the planned clinical workflow.
  • Inspect the sterile package for punctures, moisture, damage, contamination, or compromised integrity.
  • Prepare the port-access site according to institutional antisepsis and sterile-access procedures.
  • Prime the infusion tubing and intended fluid pathways completely with an approved solution.
  • Remove air from the system before accessing the implanted port.
  • Stabilize the port and insert the non-coring needle perpendicular to the septum using an approved technique.
  • Advance the needle carefully until appropriate contact with the base of the port reservoir is achieved.
  • Verify correct placement according to institutional policy, including aspiration for blood return when clinically appropriate.
  • Flush the implanted port according to current manufacturer instructions and facility protocol.
  • Position and secure the tubing to reduce pulling, twisting, pressure, and dressing disruption.
  • Apply an approved sterile dressing and maintain appropriate site visualization.
  • Disinfect the Y-injection site before each access according to facility protocol.
  • Maintain aseptic technique whenever connecting to or manipulating the Y-site.
  • Monitor the site for pain, swelling, redness, leakage, displacement, or other complications.
  • Confirm power-injection eligibility before connecting the system to a power injector.
  • Do not exceed 5 mL per second or the lower operating limit of any connected component.
  • After therapy, flush and lock the implanted port according to the prescribed protocol.
  • Stabilize the port while withdrawing the needle and activating the safety mechanism.
  • Confirm that the needle is secured in the protective position before handling.
  • Dispose of the used device immediately in an approved sharps container.

Stop the procedure and assess the port-access system if resistance occurs during flushing, expected blood return cannot be obtained, the patient experiences unusual discomfort, or swelling, leakage, or another abnormality develops at the access site.

Certifications and Safety Standards

The BD 2671915 PowerLoc PAK Safety Infusion Set is intended for professional medical use within established vascular-access, infusion-therapy, diagnostic imaging, infection-prevention, and occupational safety programs.

The device should be incorporated into facility procedures covering implanted port assessment, sterile preparation, skin antisepsis, port access, infusion administration, connection management, dressing care, power injection, deaccessing, and sharps disposal.

The integrated safety mechanism is designed to help shield the needle after removal from the implanted port. This feature supports needlestick-prevention practices but does not replace appropriate clinician training, personal protective equipment, safe sharps handling, or immediate disposal in an approved sharps container.

The non-coring needle is intended to access the septum of a compatible implanted vascular port while helping minimize unnecessary septum damage when used correctly. Needle gauge and length must be selected according to the implanted port, patient anatomy, prescribed therapy, and manufacturer instructions.

Healthcare organizations should review current manufacturer documentation for applicable FDA clearance, UDI information, sterilization method, shelf life, material composition, natural rubber latex status, DEHP information, pressure limits, flow-rate specifications, and other technical or regulatory requirements.

Comparison with Competitors

Compared with conventional implanted port needles without integrated safety features, the BD PowerLoc system includes a safety mechanism designed to shield the needle during deaccessing. This can help reduce accidental needlestick exposure between removal and final sharps disposal.

Compared with infusion sets without a Y-injection site, BD 2671915 provides a secondary access point within the tubing. This may support compatible intermittent medication administration or connection of an additional approved fluid pathway without disconnecting the primary line.

Compared with non-power-injectable port-access sets, the PowerLoc platform supports compatible power-injection procedures when used with an approved power-injectable implanted port and within all specified pressure and flow limits.

Compared with 20-gauge and 22-gauge PowerLoc configurations, the 19-gauge needle provides a larger fluid pathway and may be selected when higher flow capability is clinically required. A larger gauge should be used only when appropriate for the implanted port and prescribed procedure.

Compared with 0.75-inch and 1-inch access needles, the 1.5-inch configuration is designed for ports positioned beneath greater tissue depth. Correct length selection is essential because excessive needle length may affect stability, while insufficient length may prevent complete septum access.

Compared with loose individual port-access supplies, the PAK presentation organizes essential components within one procedural package. This can simplify preparation and support consistency across clinicians and treatment environments.

Alternative safety infusion sets may vary in gauge, needle length, safety mechanism, power-injection capability, Y-site design, tubing configuration, included kit components, and packaging quantity. BD 2671915 combines a 19-gauge, 1.5-inch non-coring needle with a Y-injection site, safety technology, and organized PAK presentation.

Typical User Profile and Application Scenarios

The BD 2671915 PowerLoc PAK Safety Infusion Set is intended for trained healthcare professionals responsible for accessing and managing implanted vascular ports. Typical users include infusion nurses, oncology nurses, radiology nurses, vascular-access specialists, physicians, advanced practice clinicians, and other qualified clinical personnel.

Common use environments include hospitals, oncology centers, outpatient infusion clinics, diagnostic imaging departments, ambulatory treatment centers, emergency departments, specialty practices, and other healthcare facilities where implanted vascular ports are routinely accessed.

The product may be selected for patients whose implanted port depth requires a 1.5-inch access needle and whose prescribed treatment or diagnostic procedure is compatible with a 19-gauge device.

Typical application scenarios include chemotherapy administration, antibiotic infusion, hydration, parenteral nutrition, blood product delivery, blood specimen collection, routine port maintenance, and power injection of contrast media during compatible imaging procedures.

The Y-injection site is particularly useful in workflows requiring secondary access for compatible intermittent medication administration, flushing, or connection of another approved fluid pathway.

Best Practices for Use and Maintenance

The BD 2671915 is a sterile, single-use medical device and does not require maintenance as reusable equipment. Best practices focus on correct storage, product selection, sterile preparation, port-access technique, Y-site management, site monitoring, safety activation, and disposal.

  • Store unopened sets under the environmental conditions specified by the manufacturer.
  • Protect packages from moisture, excessive heat, freezing, crushing, punctures, and contamination.
  • Rotate inventory according to expiration dates and facility stock-control procedures.
  • Verify the BD 2671915 catalog number before opening the package.
  • Confirm the 19-gauge size, 1.5-inch length, and presence of the Y-injection site.
  • Assess the patient's tissue depth and implanted port position before selecting the needle length.
  • Confirm that the required therapy and flow rate are appropriate for a 19-gauge device.
  • Use strict aseptic technique during preparation, priming, insertion, connection, and dressing application.
  • Prime all intended fluid pathways completely before accessing the implanted port.
  • Stabilize the port during both needle insertion and removal.
  • Position the tubing to avoid unnecessary pulling or pressure on the access site.
  • Scrub and disinfect the Y-injection site before every access according to institutional policy.
  • Keep unused access points capped and protected from contamination.
  • Monitor the port site and tubing connections throughout therapy.
  • Verify the power-injectable status of the entire system before a powered procedure.
  • Never exceed the lowest pressure or flow-rate limit of any connected component.
  • Do not bend, cut, modify, repair, or otherwise alter the infusion set.
  • Do not reuse, clean, resterilize, or reprocess the single-use device.
  • Confirm complete safety activation immediately after needle withdrawal.
  • Place the protected device directly into an approved sharps container.

Regulatory and Safety Information

The BD 2671915 PowerLoc PAK Safety Infusion Set should be used only by appropriately trained healthcare professionals and only for applications consistent with current manufacturer labeling, implanted port instructions, professional clinical judgment, and institutional policy.

Before use, verify the product identity, 19-gauge size, 1.5-inch needle length, Y-injection site configuration, sterile package integrity, expiration date, and compatibility with the implanted vascular port. Do not use a device that is expired, damaged, contaminated, or supplied in compromised packaging.

The set should not be used for power injection unless the implanted port and every connected component are specifically rated for power injection. The permitted pressure, flow rate, contrast-media viscosity, and other operating conditions must be confirmed before beginning the procedure.

Compatible 19-gauge PowerLoc configurations support power-injection flow rates up to 5 mL per second when used under manufacturer-specified conditions. The lowest-rated component within the complete system determines the maximum allowable operating limit.

Incorrect needle-length selection, incomplete septum access, excessive pressure, needle displacement, or improper securement may cause infiltration, extravasation, tissue injury, leakage, implanted port damage, interrupted therapy, or other complications.

The Y-injection site should be accessed only with compatible devices using appropriate disinfection and aseptic technique. Improper manipulation or inadequate disinfection may increase the risk of contamination, connection failure, or bloodstream infection.

The integrated safety mechanism should be activated according to current manufacturer instructions. The used device remains a contaminated sharp after deaccessing and must be discarded immediately in an approved sharps container.

The product is supplied five sets per case. Distributor listings identify this configuration as temperature sensitive and non-returnable. Purchasing personnel should confirm current availability, shipping eligibility, storage requirements, order quantity, and return conditions before purchasing.

How to Order

Select the BD 2671915 - PowerLoc PAK Safety Infusion Set with Y-Injection Site, 19G x 1.5" and add it to your cart. Complete checkout with your preferred shipping and payment options. For bulk orders, quotes, or further assistance, contact CIA Medical customer service at (312)275-5850 or use the contact form on this page.

[1]: https://www.bd.com/en-us/products-and-solutions/products/product-page.2671915 "PowerLoc Safety Infusion Set PAK with Y-Injection Site, 19 G x 1.5 in. - 2671915 | BD"

Related Products